These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8416177)

  • 21. Aluminum and iron overload in chronic dialysis.
    Ackrill P; Day JP; Ahmed R
    Kidney Int Suppl; 1988 Mar; 24():S163-7. PubMed ID: 3283407
    [No Abstract]   [Full Text] [Related]  

  • 22. [The deferoxamine loading test as a non-invasive method for diagnosing Al-related bone disease in hemodialysis patients; efficacy of deferoxamine therapy for the disease].
    Umetani N; Sato N; Yoshida A; Marumo F
    Nihon Jinzo Gakkai Shi; 1988 Feb; 30(2):143-50. PubMed ID: 3386018
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
    Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
    Lechleitner P; Gmeiner R; Beck G; König P
    Wien Med Wochenschr; 1987 Aug; 137(14-15):355-60. PubMed ID: 3673100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
    Swartz R; Dombrouski J; Burnatowska-Hledin M; Mayor G
    Am J Kidney Dis; 1987 Mar; 9(3):217-23. PubMed ID: 3826071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Dialysis bone disease associated with other factors].
    Nakazawa R
    Nihon Rinsho; 1992 Jan; 50 Suppl():789-95. PubMed ID: 1578768
    [No Abstract]   [Full Text] [Related]  

  • 27. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 28. Aluminum intoxication of bone in renal failure--fact or fiction?
    Malluche HH; Faugere MC; Smith AJ; Friedler RM
    Kidney Int Suppl; 1986 Feb; 18():S70-3. PubMed ID: 3458000
    [No Abstract]   [Full Text] [Related]  

  • 29. Fracture healing with deferoxamine therapy in a patient with aluminum-associated osteomalacia.
    Phelps KR; Einhorn TA; Vigorita VJ; Lundin AP; Friedman EA
    ASAIO Trans; 1986; 32(1):198-200. PubMed ID: 3778712
    [No Abstract]   [Full Text] [Related]  

  • 30. Bone histologic response to deferoxamine in aluminum-related bone disease.
    Andress DL; Nebeker HG; Ott SM; Endres DB; Alfrey AC; Slatopolsky EA; Coburn JW; Sherrard DJ
    Kidney Int; 1987 Jun; 31(6):1344-50. PubMed ID: 2441107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aluminum kinetics of the REDY system: a study of the impact of deferoxamine therapy.
    Culpepper CP; Cummings R; Westervelt FB; Savory J; Wills MR
    Trans Am Soc Artif Intern Organs; 1983; 29():76-80. PubMed ID: 6673321
    [No Abstract]   [Full Text] [Related]  

  • 32. Recent developments in aluminum toxicology.
    Monteagudo FS; Cassidy MJ; Folb PI
    Med Toxicol Adverse Drug Exp; 1989; 4(1):1-16. PubMed ID: 2651849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy of aluminum overload (I).
    Pierides AM; Myli MP
    Contrib Nephrol; 1984; 38():65-77. PubMed ID: 6425013
    [No Abstract]   [Full Text] [Related]  

  • 34. Aluminum: a pediatric overview.
    Gruskin AB
    Adv Pediatr; 1988; 35():281-330. PubMed ID: 3055861
    [No Abstract]   [Full Text] [Related]  

  • 35. Osteomalacia and bone disease arising from aluminum.
    Coburn JW; Norris KC; Nebeker HG
    Semin Nephrol; 1986 Mar; 6(1):68-89. PubMed ID: 3110896
    [No Abstract]   [Full Text] [Related]  

  • 36. [Current concepts of the role of aluminum in chronic kidney failure patients].
    Gruev I; Belovezhdov N
    Vutr Boles; 1983; 22(2):1-4. PubMed ID: 6362201
    [No Abstract]   [Full Text] [Related]  

  • 37. Anaemia and aluminium chelation therapy in dialysis patients.
    Tielemans C; Collart F; Wens R; Smeyers-Verbeeke J; Van Hooff I; Dratwa M; Verbeelen D
    Lancet; 1988 Jul; 2(8604):220. PubMed ID: 2899690
    [No Abstract]   [Full Text] [Related]  

  • 38. The early effects of aluminium deposition and dialysis on bone in chronic renal failure: a cross-sectional bone-histomorphometric study.
    Dahl E; Nordal KP; Halse J; Flatmark A
    Nephrol Dial Transplant; 1990; 5(6):449-56. PubMed ID: 2122323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 40. Aluminium toxicity in chronic renal insufficiency.
    Savory J; Bertholf RL; Wills MR
    Clin Endocrinol Metab; 1985 Aug; 14(3):681-702. PubMed ID: 3905084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.